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MicroRNAs are short, endogenous RNAs that direct posttranscriptional regulation of gene expression vital for many develop-
mental and cellular functions. Implicated in the pathogenesis of several human diseases, this group of RNAs provides interesting
targetsfortherapeuticintervention.Anti-microRNAoligonucleotidesconstituteaclassofsyntheticantisenseoligonucleotidesused
to interfere with microRNAs. In this study, we investigate the eﬀects of chemical modiﬁcations and truncations on activity and
speciﬁcity of anti-microRNA oligonucleotides targeting microRNA-21. We observed an increased activity but reduced speciﬁcity
when incorporating locked nucleic acid monomers, whereas the opposite was observed when introducing unlocked nucleic
acid monomers. Our data suggest that phosphorothioate anti-microRNA oligonucleotides yield a greater activity than their
phosphodiester counterparts and that a moderate truncation of the anti-microRNA oligonucleotide improves speciﬁcity without
signiﬁcantly losing activity. These results provide useful insights for design of anti-microRNA oligonucleotides to achieve both
high activity as well as eﬃcient mismatch discrimination.
1.Introduction
OriginallyidentiﬁedinCaenorhabditiselegansandsubseque-
ntly established in a number of additional organisms includ-
ing mammalian cells [1–3], RNA interference (RNAi) is a
posttranscriptional gene-silencing process targeting single-
stranded RNA sequences. Whereas several classes of RNAi
eﬀectors have been identiﬁed, siRNAs and microRNAs
(miRNAs) are the best characterized.
miRNAs interact with transcript sequences possessing
partial or full complementarity, promoting gene repression
of the targeted transcripts. Dysregulation of miRNAs has be-
en implicated in human developmental disorders and diseas-
es, including several forms of cancer [4–6]. Manipulation of
miRNAs, utilizing synthetic, chemically modiﬁed oligonu-
cleotides (ONs) targeting select miRNAs, presents an appro-
ach to both elucidate the role of miRNA dysregulation
in human disease and discover novel therapies for many
pathological conditions. miRNAs have previously been
shown to possess the ability to regulate multiple functionally
r e l a t e dm R N A s ,s u c ha ss e t so fm e t a b o l i cg e n e s[ 7, 8], a
powerful feature that may enable miRNA-based therapeutics
to circumvent redundant mechanisms that might otherwise
bypass single inhibited targets.
miRNA-21(miR21)ispotentiallyaveryinterestingtarget
for future therapeutic applications. It has widespread regula-
tory functions and has been implicated in a variety of dis-
eases, including cancer and heart disease [9, 10]. It is overex-
pressedinmanyformsofhumancancersandhasbeenshown
to be an important regulator of many tumor suppressors [9,
11–14].
ON technologies provide speciﬁc and powerful means
for targeting biologically active nucleic acids for inhibition.2 ISRN Pharmaceutics
Table 1: Oligonucleotides used in this study.The anti-miR21 ONs used in this study, ranging from 9 to 22 nucleotides in length.
The ONs are 2 OMe RNA, LNA/2 OMe RNA mixmers with or without phosphorothioate backbone, and LNA/2 OMe/UNA mixmers.
Corresponding ONs with 2MMs were synthesized. Mismatched bases are mismatched against the bases 9 and 11 in the target miR21
sequence. Phosphorothioate AMOs are denoted with PS, ONs lacking this denotation are phosphodiester AMOs. Capital letters represent
2 OMe ribonucleotides. Lowercase letters indicate LNA monomers, whereas underlined letters represent UNA monomers. Italic letters mark
mismatches and bold letters phosphorothioates.
Sequence Name Chemistry Mismatches LNA-mismatches
3 - AGU UGU AGU CAG ACU AUU CGA U-5  Original miR21 sequence 0 0
5 -UCA ACA UCA GUC UGA UAA GCU A-3  22AMO 0% LNA 0 0
5 -UCA ACA UCU GACU G AU A AG C UA - 3   22AMO 2MM 0% LNA 2 0
5 - UcA aCa UcA gUc UgA uAa GcU a-3  22AMO 50% 50% LNA 0 0
5 -U c Aa C aU c U gAc UgA uAa GcU a-3  22AMO 50% 2MM 50% LNA 2 0
5 - UcA AcA UcA GuC UgA UaA GcU A-3  22AMO 32% 32% LNA 0 0
5 -U c AA c AU c U GaCU g AU a AG c UA - 3   22AMO 32% 2MM 32% LNA 2 1
5 - U c AA c AU c AG u CU g AU a AG c UA -3  22AMO 32% PS PS 32% LNA 0 0
5 - UcA AcA UcU GaCU g AU a AG c UA-3  22AMO 32% 2MM PS PS 32% LNA 2 1
5 - AcA UcA GuC UgA UaA GcU -3  18AMO 33% 33% LNA 0 0
5 -A c AU c U GaCU g AU a AG c U- 3   18AMO 33% 2MM 33% LNA 2 1
5 -A c AU c AG u CU g AU a A- 3   15AMO 33% 33% LNA 0 0
5 -A c AU c U GaCU g AU a A- 3   15AMO 33% 2MM 33% LNA 2 1
5 - AcA UcA GuC UgA -3  12AMO 33% 33% LNA 0 0
5 -A c AU c U GaCU g A- 3   12AMO 33% 2MM 33% LNA 2 1
5 -U c AG u CU g A- 3   9AMO 33% 33% LNA 0 0
5 -U c U GaCU g A- 3   9AMO 33% 2MM 33% LNA 2 1
5 -UcA AcA UcA GuC UgA UaA GcU A-3  22AMO 68% PS PS 68%
LNA,32%UNA 00
5 -UcA AcA UcU Ga C UgA UaA GcU A-3  22AMO 68% 2MM PS PS 68%
LNA,32%UNA 21
5 - uCaacauCaguc uGau a ag C ua -3  22AMO 68% PS PS 68%
LNA,18%UNA 00
5 - uCa aca uCugAcu G au a ag C ua-3  22AMO 68% 2MM PS PS 68%
LNA,18%UNA 21
Unmodiﬁed DNA ONs have previously been shown to be
less eﬀective as inhibitors due to chemical instability in
vivo [15]. Subsequently, chemical modiﬁcation of nucleotide
monomershasbeenexploredasameanstomodulateaﬃnity
and bioactivity of nucleic acids [16–19]. The most important
property of chemically modiﬁed ONs is speciﬁcity and high
binding aﬃnity to RNA. A number of chemically altered
nucleotides with increased binding aﬃnity have been syn-
thesized. Optimally, an anti-miRNA oligonucleotide (AMO)
should be stable in vivo, hybridize eﬃciently and speciﬁcally
with the target miRNA, be nontoxic and nuclease resistant.
The 2 -O-methyl RNA (2 OMe RNA) possesses increased
nuclease resistance and improved base-pairing aﬃnity as
compared to both DNA and RNA. Incorporation of locked
nucleic acid (LNA) monomers confers a well-documented
aﬃnity enhancement to complementary sequences [20–23].
Unlocked nucleic acid (UNA) is an acyclic RNA analogue
that has been shown to destabilize duplexes formed between
UNA-modiﬁed RNA strands and complementary DNA or
RNA. As such, UNA monomers are able to modulate base-
pairing speciﬁcity and duplex stability [24]. Phosphoroth-
ioates are a variant of normal DNA in which one of the
nonbridging oxygens in the phosphate backbone is replaced
by sulphur. This chemical modiﬁcation has been shown
to drastically improve nuclease resistance as well as the
ability to cross the lipid bilayer of the cell membrane
[25].
In the present study a set of AMOs complementary to
miR21 were synthesized (Table 1) .T h eA M O sd i ﬀered in
length and chemical composition, such as the amount and
type of synthetic nucleotide monomers incorporated. Corre-
sponding AMOs with two mismatches were utilized to assess
mismatch discrimination.
The main scope of our study was to assess the eﬀects on
AMO speciﬁcity and activity conveyed by synthetic nucleoti-
des with diﬀerent chemical modiﬁcations and ON length.
2.MaterialsandMethods
2.1. Synthesis of Oligonucleotides. The phosphorothioate
2 OMe RNA AMOs were synthesized on a ¨ AKTA oligopilot
plus 10 synthesizer (GE Healthcare) and puriﬁed as previ-
ouslydescribed[26].AllAMOs,phosphorothioateandphos-
phodiester, with LNA or UNA content were obtained fromISRN Pharmaceutics 3
RiboTask. All phosphorothioate AMOs are denoted with PS;
ONs lacking this denotation are phosphodiester AMOs.
2.2. Cell Culture. H e L ac e l l sw e r eg r o w ni nD M E M( D u l -
becco’s modiﬁed Eagle’s medium) with glutamax supple-
mented with 0.1mM nonessential amino acids, 1.0mM so-
dium pyruvate, 10% fetal bovine serum (FBS), 100units/ml
penicillin, and 100mg/ml streptomycin. Cells were cultured
at 37◦Ci na5 %C O 2 atmosphere. All media and chemicals
were purchased from Invitrogen.
2.3. Anti-MiRNA Assay. To evaluate the AMOs we used a
psiCHECK-2 vector (Promega) with a miR21-binding site
cloned into the 3  UTR of the Renilla luciferase gene. In
addition to the Renilla luciferase gene, the psiCHECK-2
vector also contains a constitutively active ﬁreﬂy luciferase
gene used for normalization of protein content. In the
absence of an AMO to provide eﬀective miRNA inhibition,
endogenous miR21 blocks Renilla luciferase expression.
Thus the level of Renilla luciferase expression will be a
measurement of the AMO activity.
HeLa cells (600 000 cells) were plated in a 60mm dish.
24 hours later 2µg PsiCHECK-2 plasmid was transfected
with 4µl of Lipofectamine 2000. The transfection mix was
added to the cells growing in 4ml of medium. 24 hours later
cells were trypsinized and counted. 60 000 cells/well were
replated in 24 well plates (Sigma-Aldrich) with 1ml DMEM
+ 10% FBS. 24 hours after plasmid transfection, anti-miR21
ONs were transfected using Lipofectamine 2000, in a total
volume of 500µL. Anti-miR21 ONs were transfected in
triplicates at100nM,50nM,25nM,or 10nM. After6 hours,
500µL DMEM + 10% FBS was added to each well. 24
hours after anti-miR21 transfection, cells were lysed and
luciferaseactivityof20µLofcelllysatewasmeasuredinRLUs
(relative luminescence units) on a GloMax 96 microplate
Luminometer (GloMax) using the Dual-Luciferase Reporter
Assay System (Promega). The results are presented as
normalized luciferase activity, which corresponds to the
increase of luciferase activity compared to untreated cells.
Experimentswereperformedatleastthreetimesintriplicate.
2.4. Statistical Analyses. All results are mean ±SEM for at
least two independent experiments performed in triplicate.
Statistics were calculated using two-tailed paired t-tests
(∗∗∗P<0.001, ∗∗P<0.01, ∗P<0.05).
3. Results
3.1. Design of AMOs. To assess and compare the impact
on AMO activity mediated by diﬀerent synthetic ONs and
ON length we designed a set of ONs targeting miR21 using
diﬀerent ON chemistries and lengths (Table 1). ON length
ranged from 9 nucleotides to 22 nucleotides. Synthesized
ONs were 2 OMe RNA, LNA/2 OMe RNA mixmers with or
withoutphosphorothioatebackbone,andLNA/2 OMe/UNA
mixmers (Table 1), all targeting miR21. Content of UNA
and LNA is given as percent, any remaining nucleotides are
2 OMe ribonucleotides.
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Figure 1: Oligonucleotide length eﬀects on AMO activity. Fold
increase of luciferase activity after wild-type AMO treatment at
three diﬀerent concentrations, 100nM, 50nM, and 25nM. Five
diﬀerent lengths were used, a 22-, 18-, 15-, 12-, and 9-mer (data
not shown) ONs. All AMOs had a phosphodiester (PO) backbone.
We designed LNA/2 OMe/UNA mixmers to investigate
whetheritwaspossibletouseUNAtomodulateanypotential
negative impact on mismatch discrimination mediated by
LNA. Such eﬀects of LNA on speciﬁcity were previously
reported for splice-switching ONs (SSOs) with LNA content
[26]. In order to evaluate eﬀects on speciﬁcity, we syn-
thesized corresponding ONs with two mismatches (2MM)
to the targeted miR21. Using the Dual-Luciferase Reporter
Assay System (Promega), an increase in luciferase activity
normalized against untreated cells was used as indication of
the eﬃciency of the AMOs to hybridize and interfere with
miR21 binding to the miR21-binding site in the psiCHECK-
2v e c t o r .D i ﬀerences in activity between wild-type (wt)
AMOs and their corresponding control ONs with two bases
mismatchedforthetargetsequencewasusedasanindication
of speciﬁcity. All mismatched bases were mismatched against
the bases 9 and 11 in the target miR21 sequence.
3.2. Oligonucleotide Length Optimization. As previous stud-
ies have shown that a moderate reduction of ON length
not necessarily compromises the activity [27], we tested a
range of AMOs of various lengths to see if truncation had
similar eﬀects on the activities of the AMOs. The activity
was not signiﬁcantly diﬀerent between the 22-nucleotide-
long ON and the 18-nucleotide-long ON. However, at a
length of 15 nucleotides or shorter the activity was all
but abolished completely (Figure 1). The 9-mers did not4 ISRN Pharmaceutics
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Figure 2: Inﬂuence of oligonucleotide length on AMO speciﬁcity.
Fold increase of luciferase activity posttreatment at 100nM con-
centration with a 32% LNA 22-mer AMO and 33% LNA 18-
mer, both with phosphodiester backbone. The 18-mer AMO has
a comparative activity to that of the 22-mer AMO but the AMO
with two mismatches has lower activity than the corresponding 22-
mer with two mismatches, indicating better sequence speciﬁcity for
target miR21.
display any activity and were thus omitted from the ﬁgures.
Concomitantly, the diﬀerence in activity between wt and
2MM AMOs was signiﬁcant for the AMOs with a length
of 18 nucleotides as opposed to the full 22-nucleotide-long
AMOs (Figure 2). Thus the 18-mers displayed a greater
discrimination against mismatches, and therefore a higher
speciﬁcity, than the 22-mers. Additionally, the activity of
the 18-mer was signiﬁcantly lower at lower concentrations,
whereas the dose dependency of the activity of the 22-mer
was not as statistically acute.
3.3. Oligonucleotide Modiﬁcation Eﬀects on AMO Activity and
Speciﬁcity. We investigated the eﬀects on AMO activity me-
diated by phosphodiester chemistry by comparing the ac-
tivity of phosphorothioate LNA/2 OMe RNA mixmers to
that of phosphodiester LNA/2 OMe RNA mixmers at four
diﬀerent concentrations, 100nM, 50nM, 25nM, and 10nM.
The activity for the LNA/2 OMe RNA mixmers with a phos-
phorothioate backbone was signiﬁcantly greater than those
with a normal phosphodiester backbone at all tested concen-
trations, respectively (Figure 3).
We also investigated the eﬀects on AMO interaction
with miR21 mediated through introduction of LNA into
AMOs. LNA-enhanced activity is supported by the well-
characterized high binding aﬃnity for LNA residues [18].
The addition of LNA monomers resulted in an increase in
activity but at the cost of reduced speciﬁcity, except in the
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Figure 3: Inﬂuence of phosphorothioates on AMO activity. Fold
increase of luciferase activity after wild-type AMO treatment at
100nM, 50nM, 25nM, and 10nM concentrations. The AMO
activity was at all concentrations signiﬁcantly greater for the
phosphorothioate (PS) ONs than the activity of the phosphodiester
ONs.
case of the phosphorothioate LNA/2 OMe mixmer (Figure
4). The activity of the AMO with 32% LNA was not signif-
icantly diﬀerent from that of the 50% LNA AMO (Figure 4).
The LNA/2 OMe/UNA mixmers with a UNA content
of 32% displayed virtually no activity, whereas signiﬁcant
activity was obtained using similar mixmers with 18% UNA.
High UNA content appeared to all but totally abolish the
AMO activity but lower UNA content exhibits mismatch
discrimination (Figure 5).
4. Discussion
MiRNAs, one of several types of RNAi eﬀectors, provide
possible therapeutic targets to combat human diseases and
developmental disorders. They also provide a platform to
further the understanding of the mechanisms of RNA in-
terference. AMOs can be used for this purpose as either a
therapeutic agent [28, 29] or as a tool to study miRNAs.
Some of the key properties of an ideal AMO for therapeutic
purposes would be serum stability, a high activity at low
concentrations, and a high speciﬁcity for its target sequence.
InthepresentstudyweusedasetofsynthesizedAMOsof
diﬀerent lengths and diﬀerent nucleotide chemistries to tar-
getmiR21,acommonlyexpressedmiRNA,andanimportant
regulator of cancer-cell survival [11–14]. Our results suggest
that while introducing LNA monomers into the AMOs
improvestheactivityitalsoreducesthespeciﬁcity(Figure 4),
which is important to consider when designing AMOs. This
is consistent with observations done in experiments withISRN Pharmaceutics 5
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Figure 4: LNA and phosphorohioate eﬀects on AMO activity and
speciﬁcity. Fold increase of luciferase activity after AMO treatment
at 100nM concentrations. The amount of LNA monomers incor-
porated in the oligonucleotides used varied between 0% and 50%.
No signiﬁcant disparity in activity was seen between 32% and 50%
LNA content. The activity of AMOs with 32% and 50% LNA was
signiﬁcantly greater than with 0% LNA. Phosphorothioate AMO
with 32% LNA and AMO absent of LNA both showed a signiﬁcant
diﬀerence in activity between wildtype and mismatched construct.
splice-switching oligonucleotides (SSOs) and antisense LNA
mixmers [13, 26, 30].
Changing the AMO backbone chemistry provides yet
another means to modulate activity and speciﬁcity. Our
results indicate that LNA mixmer AMOs with a phos-
phorothioate backbone yield a much greater activity than
with a phosphodiester backbone (Figure 3). This could
in part be explained by a better cellular binding and
uptake as well as better serum stability of the phospho-
rothioate AMO compared to AMOs with a phosphodiester
chemistry [31]. Phosphorothioate AMOs also displayed
good mismatch discrimination despite a 32% LNA content
(Figure 4). Phosphorothioate linkages lower binding aﬃnity
by ∼0.43◦C/linkage which can increase speciﬁcity [32].
However, PS linkages may cause toxicity through nonspeciﬁc
interactions with proteins [33].
Besidesintroducingaphosphorothioatebackbonechem-
istry, the negative impact on mismatch discrimination con-
veyed by the LNA monomers appears to be possible to coun-
teract through a shortening of the ON. Our results show that
it is possible to shorten the AMO while retaining activity and
that the 18-mer displays improved mismatch discrimination
compared to the full-length 22-mer AMO (Figure 2). This is
in accordance with previous studies of antisense ON length
eﬀects on activity, showing the possibility of retaining a high
activity with shortened ONs [27]. In addition, recent studies
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Figure 5: Inﬂuence of UNA monomers on AMO activity. Fold
increaseofluciferaseactivitymeasuredaftertreatmentwith100nM
AMO, comparing the 22AMO with phosphorothioate backbone
and 32% LNA with the 22AMO with LNA/UNA. UNA content
improved mismatch discrimination.
show that the speciﬁcity of particularly higher potency com-
pounds beneﬁt from use of lower dosages [34].
UNA has previously been reported to have duplex-de-
stabilizing properties [24]. Consequently, LNA/UNA mix-
mers were used to explore the possibility to modulate the
duplex-stabilizing property of LNA mixmers with the desta-
bilizing property of the UNA monomers. This was done to
assess whether introducing UNA monomers could reduce
the negative impact of LNA on mismatch discrimination.
However, the 68% LNA and 32% UNA AMO used in the
study displayed virtually no activity (Figure 5) making a
speciﬁcity comparison impossible. It appears the LNA to
UNA ratio was not balanced enough to prevent the detri-
mentaleﬀectofUNAmonomersonduplexstabilitytoallbut
completely abolish the AMO activity. A signiﬁcant albeit low
activity was obtained by performing the experiment using
mixmers with 18% UNA content instead. Moreover, those
mixmers displayed a signiﬁcant mismatch discrimination
(Figure 5), whereas the LNA/2 OMe mixmer completely
lacking UNA did not (Figure 4).
In summary, our results suggest that introducing LNA
monomers to 2 -OMe RNA ONs enhances AMO activity but
mismatch discrimination is adversely aﬀected. An increased
activity can also be obtained through chemical modiﬁcation
of the ON backbone as a phosphorothioate ON with LNA6 ISRN Pharmaceutics
monomers introduced. AMOs which are 18-nucleotide-long
LNA/2 -OMe RNA mixmers display an activity comparable
to full-length 22-mers but with higher speciﬁcity. This
could be of importance during ON design as designing
shorter AMOs could compensate potential toxicity due to
low mismatch discrimination. The negative eﬀect of LNA
on speciﬁcity to target miRNAs has to be considered when
utilizing LNA monomers in mixmers for targeting miR-
NAs. Although our results showed no signiﬁcant diﬀerence
in speciﬁcity between AMOs with 32% and 50% LNA
(Figure 4) it might be possible to improve the speciﬁcity
through tuning of the proportion of LNA content. The
addition of UNA monomers may contribute to improved
mismatch discrimination yet abolishes AMO activity if the
content is high.
5. Conclusions
Our observations are generally in accordance with previous
studies. AMOs modiﬁed with LNA and/or phosphoroth-
ioates were very potent in vitro using miR21 reporter assay
systems yet we observed a deleterious eﬀect on speciﬁcity
caused by the introduction of LNA monomers. UNA-
modiﬁed AMOs displayed a drastically reduced potency but
conversely appeared to improve the speciﬁcity. Furthermore,
reducing the length of the AMO from 22 nucleotides to
18 nucleotides improves mismatch discrimination while
retaining activity. This highlights the possibility to balance
the potent activity-enhancing modiﬁcations such as LNA
with speciﬁcity-improving modiﬁcations such as truncation
and moderate incorporation of UNA monomers. These
data should aid researchers in rational design of AMO and
furtherinvestigationsofmodiﬁcationschemessuitedtotheir
individual requirements.
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